Total baseline tumor size predicts survival among patients with advanced small-cell lung cancer receiving chemotherapy plus programmed death-ligand 1 inhibitor as first-line therapy: a multicenter retrospective observational study
Total BTS is a potentially useful prognostic factor for patients with advanced SCLC who receive chemotherapy plus PD-L1 inhibitor as first-line therapy.
Authors
- Ayami Kaneko
- Yu Sairenji
- Yukihito Kajita
- Nobuaki Kobayashi (ORCID: https://orcid.org/0000-0002-7064-320X)
- Naoki Miyazawa (ORCID: https://orcid.org/0000-0003-2983-7106)
- Shuhei Teranishi (ORCID: https://orcid.org/0000-0003-2365-144X)
- Masaki Yamamoto (ORCID: https://orcid.org/0000-0001-7056-4192)
- Kenji Miura (ORCID: https://orcid.org/0000-0003-2763-5981)
- Makoto Kudo (ORCID: https://orcid.org/0000-0002-1837-0267)
- Takeshi Kaneko (ORCID: https://orcid.org/0000-0001-9292-307X)
- Toshinori Tsukahara
- Hidetoshi Kawashima (ORCID: https://orcid.org/0000-0003-1163-5389)
- Kentaro Yumoto (ORCID: https://orcid.org/0000-0003-1344-5052)
- Ryuichi Nishihira
- Anna Tanaka
- Masanori Nishikawa (ORCID: https://orcid.org/0000-0003-4253-5153)
- Tomofumi Hirose
Institutions
- Fujisawa City Hospital (JP)
- Yokohama City University Medical Center (JP)
- Yokohama Minami Kyosai Hospital (JP)
- Kansai Rosai Hospital (JP)
- Yokohama Sakae Kyosai Hospital (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-11-04
- DOI
- https://doi.org/10.3389/fonc.2024.1400277
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00